“Patients who failed to sustain SVR had persistently detectable viremia, the researchers wrote, while IL28B CC was associated with SVR.”
Kathleen B. Schwarz, MD, professor of pediatrics and
director of the Pediatric Liver Center at Johns Hopkins University
School of Medicine, and colleagues conducted long term follow-up of 5 to
6 years on 38 patients who participated in phase 2 or 3 of the PEDS C
The initial trial included 114 children with chronic hepatitis C (CHC) who were treated with pegylated interferon (PegIFN) alfa-2a at 180 mcg/1.73 m2 subcutaneously weekly with or without ribavirin
(RBV) at 15 mg/kg/day or placebo for 48 weeks. Patients who received
PegIFN and placebo and did not respond at 24 weeks, crossed over to
PegIFN/RBV for 24 to 48 weeks.
During the PEDS C trial, overall sustained virologic response (SVR) was 53% with PegIFN and RBV; 75 patients were nonresponders, while 39 responded to treatment.
Cost regulators in England and Wales have backed the use of peginterferon alfa on the National Health Service to treat children with hepatitis C.
The National Institute for Health and Care Excellence has this morning published draft guidance recommending a combination of peginterferon alfa and ribavirin as an option for chronic forms of the disease in children and young people.
Consequently, Roche’s Pegasys (peginterferon alfa-2a) and Merck Sharp and Dohme’s ViraferonPeg (peginterferon alfa-2b) will now be on the NHS treatment menu, being the only ones currently licensed in the UK for the treatment of chronic hepatitis C in children and adolescents.
February 8, 2013 – In a phase 2b, multicenter, double blind trial, researchers randomly assigned treatment-naive patients with chronic HCV genotype 1 or 4 to receive either 1,000 mg mericitabine (Genentech) (n=81) or placebo (n=85) twice daily for 24 weeks, in addition to a 48-week regimen of pegylated interferon alfa-2a and ribavirin. Treated patients who achieved extended rapid virologic response (eRVR, defined as HCV RNA levels below 15 IU/mL between weeks 4 and 22) discontinued therapy after 24 weeks, while remaining patients completed the peginterferon/ribavirin regimen.
Paul J. Pockros: “Most believe that nucleoside polymerase inhibitors [NPI] will be the backbone of antiviral therapies for HCV,” researcher Paul J. Pockros, MD, director of the Liver Disease Center and the SC Liver Research Consortium at Scripps Clinic in La Jolla, Calif., told Healio.com. “The first NPI was R1626 (balapiravir), [which] proved to be potent, but toxic. Therefore, the critical need was to develop a safe NPI.”